Ras Protein and Pancreas Cancer

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 7: Line 7:
== Disease ==
== Disease ==
-
The absence of, or mutations of these proteins cause major diseases, cancers in lungs, bladder, pancreas, and heart are the most common but not the only ones. These proteins are very important for everything because they control a lot of functions in cells. The absence of, or mutations of these signaling proteins can cause terrible damage to our body. The gene KRas which produces the KRas protein, this protein participates in cellular signaling, it controls the growth and death of cells. The normal form of this protein is natural KRas but when it gets mutated, different types of cancer can be found such as lung, colorectal and pancreas. Having these changes (mutations) might have a possible stimulation in the cells’ growth causing this the spreading of the cells in the body. Is key to verify if the tumor has the shape of a mutated or natural KRas gene so that the treatment of the cancer can be planified.
+
The absence of, or mutations of these proteins cause major diseases, cancers in lungs, bladder, pancreas, and heart are the most common but not the only ones. These proteins are very important for everything because they control a lot of functions in cells. The absence of, or mutations of these signaling proteins can cause terrible damage to our body. The gene KRas which produces the KRas protein, this protein participates in cellular signaling, it controls the growth and death of cells. The normal form of this protein is natural KRas but when it gets mutated, different types of cancer can be found such as lung, colorectal and pancreas. Having these changes (mutations) might have a possible stimulation in the cells’ growth causing this the spreading of the cells in the body. Is key to verify if the tumor has the shape of a mutated or natural KRas gene so that the treatment of cancer can be planified.
-
The RAS family of small GTPases includes three genes: HRAS, NRAS, and KRAS. Each RAS protein is comprised of two major domains, the G domain and the membrane targeting domain <ref name='Daniel'>PMID: 27096871</ref>. All of the isoforms are similar in the amino acid sequence of the G domain with major differences being restricted to the hypervariable region of their C-terminal domains. Mutations in RAS occur in residues 12, 13 and 61, and inhibit GTP hydrolysis activity (Daniel ZeitouniOrcID, 2016). The three RAS genes constitute the most frequently mutated oncogene family in human cancers; however, the specific isoform and amino acid mutation
+
The RAS family of small GTPases includes three genes: HRAS, NRAS, and KRAS. Each RAS protein is comprised of two major domains, the G domain and the membrane targeting domain <ref name='Daniel'>PMID: 27096871</ref>. All of the isoforms are similar in the amino acid sequence of the G domain with major differences being restricted to the hypervariable region of their C-terminal domains. Mutations in RAS occur in residues 12, 13 and 61, and inhibit GTP hydrolysis activity <ref name='Daniel'>PMID: 27096871</ref>. The three RAS genes constitute the most frequently mutated oncogene family in human cancers; however, the specific isoform and amino acid mutation vary among cancers (Daniel ZeitouniOrcID, 2016). Mutations in HRAS are most frequently found in melanoma, bladder, and mammary carcinoma; NRAS mutations are found in melanoma and thyroid carcinoma, and KRAS mutations are most prevalent in cancers of the bladder, ovary, thyroid, lung, colon, and pancreas. In pancreatic cancer, mutations in codon 12 of KRAS occur the most frequently <ref name='Daniel'>PMID: 27096871</ref>. RAS proteins play an active role in cell differentiation, proliferation, migration, and apoptosis, making them important in cancer signaling <ref name='Daniel'>PMID: 27096871</ref>. Individual RAS proteins are activated when they are bound to guanosine triphosphate (GTP) and are inactive when they are bound to guanosine diphosphate (GDP). Intrinsic RAS GTP-GDP cycling is regulated by guanine nucleotide exchange factors (GEFs) that stimulate nucleotide exchange and by GTPase activating proteins (GAPs) that accelerate the intrinsic GTP hydrolysis activity of RAS <ref name='Daniel'>PMID: 27096871</ref>. Once activated, RAS-GTP preferentially interacts with a spectrum of catalytically diverse downstream effectors that then regulate a myriad of cytoplasmic signaling networks <ref name='Daniel'>PMID: 27096871</ref>. KRAS plays a vital role in PDAC and is believed to be a key target for treatment. Decades of research have shaped our understanding of the biochemistry, structure, and cellular signaling of KRAS in cancer. This foundation of knowledge can be viewed in two ways: support for the need to find different routes to silence KRAS or fodder for the notion that KRAS is “undruggable” <ref name='Daniel'>PMID: 27096871</ref>. By undruggable, it means that there is no such drug yet invented that can inhibit KRAS mutation 100%. However there are some ideas to approach an effective treatment for pancreatic ductal adenocarcinoma (PDAC), one of them is direct inhibition of Ras, it is the best approach so far and it consists of small molecules identified as direct binders that altered RAS function targeted the site on RAS involved in its recognition by the RAS-GEF, SOS1. SOS1 catalyzes the exchange of GDP to GTP, the rate-limiting step in RAS activation, and thus regulates RAS activity <ref name='Daniel'>PMID: 27096871</ref>. In recent studies, RNA interference has been used to suppress KRAS expression, this has been validated as therapeutic strategies in mouse models of cancer <ref name='Daniel'>PMID: 27096871</ref>.
-
varies among cancers (Daniel ZeitouniOrcID, 2016). Mutations in HRAS are most
+
-
frequently found in melanoma, bladder and mammary carcinoma; NRAS mutations are found in melanoma and thyroid carcinoma; and KRAS mutations are most prevalent in
+
-
cancers of the bladder, ovary, thyroid, lung, colon and pancreas. In pancreatic cancer, mutations in codon 12 of KRAS occur the most frequently (Daniel ZeitouniOrcID, 2016). RAS proteins play an active role in cell differentiation, proliferation, migration, and apoptosis, making them important in cancer signaling (Daniel ZeitouniOrcID, 2016). Individual RAS proteins are activated when they are bound to guanosine triphosphate (GTP) and are inactive when they are bound to guanosine diphosphate (GDP). Intrinsic RAS GTP-GDP cycling is regulated by guanine nucleotide exchange factors (GEFs) that stimulate nucleotide exchange and by GTPase activating proteins (GAPs) that accelerate the intrinsic GTP hydrolysis activity of RAS (Daniel ZeitouniOrcID, 2016). Once activated, RAS-GTP preferentially interacts with a spectrum of catalytically diverse downstream effectors that then regulate a myriad of cytoplasmic signaling networks (Daniel ZeitouniOrcID, 2016). KRAS plays a vital role in PDAC and is believed to be a key target for treatment. Decades of research have shaped our understanding of the biochemistry, structure, and cellular signaling of KRAS in cancer. This foundation of knowledge can be viewed in two ways: support for the need to find different routes to silence KRAS, or fodder for the notion that KRAS is “undruggable” (Daniel ZeitouniOrcID, 2016). By undruggable, it means that there is no such drug yet invented that can inhibit KRAS mutation a 100%. However there are some ideas to approach an effective treatment for pancreatic ductal adenocarcinoma (PDAC), one of them is direct inhibition of Ras, it is the best approach so far and it consists of small molecules identified as direct binders that altered RAS function targeted the site on RAS involved in its recognition by the RAS-GEF, SOS1. SOS1 catalyzes the exchange of GDP to GTP, the rate-limiting step in RAS activation, and thus regulates RAS activity (Daniel ZeitouniOrcID, 2016). In recent studies, RNA interference has been used to suppress KRAS expression, this has been validated as therapeutic strategies in mouse models of cancer (Daniel ZeitouniOrcID, 2016).
+
== Relevance ==
== Relevance ==

Revision as of 15:18, 1 May 2019

Your Heading Here (maybe something like 'Structure')

Caption for this structure

Drag the structure with the mouse to rotate

References

  1. 1.0 1.1 1.2 1.3 1.4 1.5 Mueller MP, Goody RS. Review: Ras GTPases and myosin: Qualitative conservation and quantitative diversification in signal and energy transduction. Biopolymers. 2016 Aug;105(8):422-30. doi: 10.1002/bip.22840. PMID:27018658 doi:http://dx.doi.org/10.1002/bip.22840
  2. Mueller MP, Goody RS. Review: Ras GTPases and myosin: Qualitative conservation and quantitative diversification in signal and energy transduction. Biopolymers. 2016 Aug;105(8):422-30. doi: 10.1002/bip.22840. PMID:27018658 doi:http://dx.doi.org/10.1002/bip.22840
  3. Simon MI, Strathmann MP, Gautam N. Diversity of G proteins in signal transduction. Science. 1991 May 10;252(5007):802-8. PMID:1902986
  4. 4.0 4.1 4.2 4.3 4.4 4.5 4.6 4.7 4.8 Zeitouni D, Pylayeva-Gupta Y, Der CJ, Bryant KL. KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment. Cancers (Basel). 2016 Apr 18;8(4). pii: cancers8040045. doi:, 10.3390/cancers8040045. PMID:27096871 doi:http://dx.doi.org/10.3390/cancers8040045

Proteopedia Page Contributors and Editors (what is this?)

Diego Coy Caicedo, Michal Harel

Personal tools